EUVIMEDSkopri EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY 4.0

The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta‐analysis

Iason Papadopoulos iD, Maksim Tishukov, Ioannis Sokolakis, Ioannis Katafigiotis, Ioannis Leotsakos, Markos Karavitakis, Julian Marcon, Christian G Stief, Nikolaos Pyrgidis iD

Andrology · 2025-11 · 13 (8) · 2235-2245

DOI: 10.1111/andr.70025 ↗

At a glance

Systematische Übersicht in Andrology, published online on 2025-03-19. Written by Iason Papadopoulos and 8 co-authors. Institution: Department of Urology, University Hospital, LMU Munich, Munich, Germany. Major MEDLINE topics: Alprostadil, Erectile Dysfunction, Vasodilator Agents, Penile Erection. Cited 3 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Erectile dysfunction (ED) affects up to 50% of men over 40. While phosphodiesterase‐5 inhibitors (PDE5i) are the first line of medical treatment, they are not always effective. Alprostadil, available in injectable, topical, and intraurethral forms, offers an alternative treatment modality.

Objectives

This systematic review and meta‐analysis aim to evaluate the efficacy and safety of topical and intraurethral forms of alprostadil. Materials and methods The objectives and methods of this systematic review and meta‐analysis were predefined in a protocol registered on PROSPERO (CRD42021260894). We systematically searched PubMed, EMBASE, and the Cochrane Library up to April 2024. Using a random‐effects model, we compared the efficacy of topical and intraurethral forms of alprostadil against placebo. Additionally, we performed a qualitative assessment of the studies using RoB‐2 and ROBINS‐I tools.

Results

The analysis included 11 randomized controlled trials and 4 non‐randomized studies, encompassing 5869 patients with a mean age of 60 ± 9.4 years. The meta‐analysis showed a statistically significant improvement in the IIEF score by 4.7 points (95% CI: 2.4–7.1, I 2 = 97%) in patients using the topical form of alprostadil compared to placebo. There was also a statistically significant improvement of ED in patients using intraurethral alprostadil compared to placebo, with a pooled odds ratio of 0.08 (95% CI: 0.04–0.16, I 2 = 54%). The most common adverse events reported were penile pain and erythema.

Discussion

These results are limited by the variability in study designs and the relatively small number of included studies in the meta‐analysis. Moreover, the low methodological quality of the included studies further limits the strength of the conclusions.

Conclusions

Topical and intraurethral alprostadil significantly improve ED symptoms compared to placebo and are generally safe, with no serious adverse events. Further trials are necessary to confirm and expand on these findings.

Subjects

MeSH terms (MEDLINE)

AlprostadilErectile DysfunctionVasodilator AgentsPenile ErectionHumansMaleAdministration, TopicalTreatment OutcomeUrethraMiddle Aged

Author keywords

alprostadilerectile dysfunctionintraurethralsafetytopicaltreatment

Substances

AlprostadilVasodilator Agents

Authors and institutions

  • Department of Urology, University Hospital, LMU Munich, Munich, Germany.
  • Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU, Munich, Germany.
  • Pettenkofer School of Public Health, Munich, Germany.
  • School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Second Department of Urology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Laparoscopy and Endourology, Central Urology, Lefkos Stavros the Athens Clinic, Athens, Greece.

ORCID profiles: Iason Papadopoulos, Nikolaos Pyrgidis

Cite

APA

Papadopoulos, I., Tishukov, M., Sokolakis, I., Katafigiotis, I., Leotsakos, I., Karavitakis, M., Marcon, J., Stief, C. G., & Pyrgidis, N. (2025). The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta‐analysis. Andrology, 13(8), 2235-2245. https://doi.org/10.1111/andr.70025

Vancouver

Papadopoulos I, Tishukov M, Sokolakis I, Katafigiotis I, Leotsakos I, Karavitakis M, et al. The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta‐analysis. Andrology. 2025;13(8):2235-2245. doi:10.1111/andr.70025

BibTeX
@article{Papadopoulos2025,
  author = {Papadopoulos, Iason and Tishukov, Maksim and Sokolakis, Ioannis and Katafigiotis, Ioannis and Leotsakos, Ioannis and Karavitakis, Markos and Marcon, Julian and Stief, Christian G and Pyrgidis, Nikolaos},
  title = {The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta‐analysis},
  journal = {Andrology},
  year = {2025},
  volume = {13},
  number = {8},
  pages = {2235--2245},
  doi = {10.1111/andr.70025}
}
Start for free →